Vimarsana
Biggest News Aggregation in the World

Page 9 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 - Vimarsana News

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a...

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (1) - Vimarsana News

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (1)

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX)...

Hillman Sets Third Quarter 2023 Earnings Release and Results Presentation Date - Vimarsana News

Hillman Sets Third Quarter 2023 Earnings Release and Results Presentation Date

CINCINNATI, Oct. 18, 2023 -- Hillman Solutions Corp. , a leading provider of hardware products and merchandising solutions, plans to host a conference call to discuss its results for the thirteen...

Merus Announces Business Update Conference Call - Vimarsana News

Merus Announces Business Update Conference Call

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA...

Merus Announces Business Update Conference Call - Merus (NASDAQ:MRUS) - Vimarsana News

Merus Announces Business Update Conference Call - Merus (NASDAQ:MRUS)

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported